Jenny C. Chang, MD

Emily Herrmann Presidential Distinguished Chair in Cancer Research & Director, Dr. Mary and Ron Neal Cancer Center
Professor of Medicine in Oncology, Academic Institute
Full Member, Research Institute
Houston Methodist
Weill Cornell Medical College


Chang Lab


Biography

Jenny Chang, MD, is the Director of the Houston Methodist Dr. Mary and Ron Neal Cancer Center and holds the Emily Herrmann Presidential Distinguished Chair in Cancer Research. She is a Professor of Cancer with the Institute for Academic Medicine and a member of the Houston Methodist Research Institute and Professor at Weill Cornell Medical School. She obtained her medical degree at Cambridge University in England and completed fellowship training in medical oncology at the Royal Marsden Hospital/Institute for Cancer Research in the United Kingdom. She was also awarded a research doctorate from the University of London. Her recent work has focused on the intrinsic therapy resistance of cancer stem cells, and the role of targeting inflammatory pathways to change tumor immune microenvironment. Dr. Chang's clinical research aims to evaluate these novel biologic agents in breast cancer patients.

Description of Research

Dr. Chang has worked in the field of tumor-initiating cells for more than ten years. After her discovery that tumor-initiating cells are chemo-resistant, and that targeting the EGFR/HER2 pathway can decrease this subpopulation, Dr. Chang has played a key role in demonstrating some of the limitations and mechanisms of tumor-initiating cells (Creighton et al., 2009; Li et al., 2008). Her work is now focused on the mechanisms that regulate TICs, as well as initiating and planning clinical trials that target this critical tumor initiating subpopulation. She is also interested in characterizing the cross-talk between these different pathways that may lead to mechanisms of resistance, and has identified some of the chief regulatory pathways involved in TIC self-renewal. She is a world-renown clinical investigator, credited as one of the first to describe intrinsic chemo-resistance of tumor-initiating cells.

Areas Of Expertise

Breast cancer Cancer Stem cells High throughput
Education & Training

MD, University of Cambridge
Research Doctorate, University of London
Publications

Tocilizumab overcomes chemotherapy resistance in mesenchymal stem-like breast cancer by negating autocrine IL-1A induction of IL-6
Chung, AW, Kozielski, AJ, Qian, W, Zhou, J, Anselme, AC, Chan, AA, Pan, PY, Lee, DJ & Chang, JC 2022, , npj Breast Cancer, vol. 8, no. 1, 30. https://doi.org/10.1038/s41523-021-00371-0

Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View
Abdelrahim, M, Esmail, A, Saharia, A, Abudayyeh, A, Abdel-Wahab, N, Diab, A, Murakami, N, Kaseb, AO, Chang, JC, Gaber, AO & Ghobrial, RM 2022, , Cancers, vol. 14, no. 7, 1760. https://doi.org/10.3390/cancers14071760

Utility of Cell-Free DNA Detection in Transplant Oncology
Reddy, T, Esmail, A, Chang, JC, Ghobrial, RM & Abdelrahim, M 2022, , Cancers, vol. 14, no. 3, 743. https://doi.org/10.3390/cancers14030743

Clinical factors and association with treatment modalities in patients with breast cancer and brain metastases who develop leptomeningeal metastases
Puri, A, Mylavarapu, C, Xu, J, Patel, TA, S.Teh, B, Tremont-Lukats, I, Chang, JC & Niravath, P 2022, , Breast Cancer Research and Treatment, vol. 193, no. 3, pp. 613-623. https://doi.org/10.1007/s10549-022-06595-3

A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer
Chung, AW, Anand, K, Anselme, AC, Chan, AA, Gupta, N, Venta, LA, Schwartz, MR, Qian, W, Xu, Y, Zhang, L, Kuhn, J, Patel, T, Rodriguez, AA, Belcheva, A, Darcourt, J, Ensor, J, Bernicker, E, Pan, PY, Chen, SH, Lee, DJ, Niravath, PA & Chang, JC 2021, , Science translational medicine, vol. 13, no. 624, abj5070. https://doi.org/10.1126/scitranslmed.abj5070

A targetable LIFR-NF-?B-LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosis
Yao, F, Deng, Y, Zhao, Y, Mei, Y, Zhang, Y, Liu, X, Martinez, C, Su, X, Rosato, RR, Teng, H, Hang, Q, Yap, S, Chen, D, Wang, Y, Chen, MJM, Zhang, M, Liang, H, Xie, D, Chen, X, Zhu, H, Chang, JC, You, MJ, Sun, Y, Gan, B & Ma, L 2021, , Nature Communications, vol. 12, no. 1, 7333. https://doi.org/10.1038/s41467-021-27452-9

Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
Bardia, A, Messersmith, WA, Kio, EA, Berlin, JD, Vahdat, L, Masters, GA, Moroose, R, Santin, AD, Kalinsky, K, Picozzi, V, OShaughnessy, J, Gray, JE, Komiya, T, Lang, JM, Chang, JC, Starodub, A, Goldenberg, DM, Sharkey, RM, Maliakal, P, Hong, Q, Wegener, WA, Goswami, T & Ocean, AJ 2021, , Annals of Oncology, vol. 32, no. 6, pp. 746-756. https://doi.org/10.1016/j.annonc.2021.03.005

Enhancing Inflammation Targeting Using Tunable Leukocyte-Based Biomimetic Nanoparticles
Zinger, A, Sushnitha, M, Naoi, T, Baudo, G, De Rosa, E, Chang, J, Tasciotti, E & Taraballi, F 2021, , ACS Nano, vol. 15, no. 4, pp. 6326-6339. https://doi.org/10.1021/acsnano.0c05792

Benchmarks for Academic Oncology Faculty
Anthony, L, Atweh, G, Bhatia, R, Carey, LA, Chang, JC, Edelman, MJ, Kantoff, PW, Markham, MJ, Messersmith, W, Nelson, EL, Oettel, K, ORegan, R, Verschraegen, CF & Vose, JM 2021, , JCO oncology practice, vol. 17, no. 3, pp. e440-e444. https://doi.org/10.1200/OP.20.00020

Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy
Anand, K, Patel, T, Niravath, P, Rodriguez, A, Darcourt, J, Belcheva, A, Boone, T, Ensor, J & Chang, J 2021, , Scientific Reports, vol. 11, no. 1, 82. https://doi.org/10.1038/s41598-020-80081-y

Acetyl-CoA Synthetase 2: A Critical Linkage in Obesity-Induced Tumorigenesis in Myeloma
Li, Z, Liu, H, He, J, Wang, Z, Yin, Z, You, G, Wang, Z, Davis, RE, Lin, P, Bergsagel, PL, Manasanch, EE, Wong, STC, Esnaola, NF, Chang, JC, Orlowski, RZ, Yi, Q & Yang, J 2021, , Cell Metabolism, vol. 33, no. 1, pp. 78-93.e7. https://doi.org/10.1016/j.cmet.2020.12.011

Analysis of the Implementation of Telehealth Visits for Care of Patients With Cancer in Houston During the COVID-19 Pandemic
Darcourt, JG, Aparicio, K, Dorsey, PM, Ensor, JE, Zsigmond, EM, Wong, ST, Ezeana, CF, Puppala, M, Heyne, KE, Geyer, CE, Phillips, RA, Schwartz, RL & Chang, JC 2021, , JCO oncology practice, vol. 17, no. 1, pp. e36-e43. https://doi.org/10.1200/OP.20.00572

ANETT: PhAse II trial of NEoadjuvant TAK-228 plus Tamoxifen in patients with hormone receptor-positive breast cancer
Koca, E, Niravath, PA, Ensor, J, Patel, TA, Li, X, Hemati, P, Wong, H, Qian, W, Boone, T, Zhao, J, Ramshesh, PV, Cohen, AL, Murthy, A, Nair, S, Darcourt, JG, Belcheva, A, Kaklamani, VG & Chang, JCN 2021, , Breast Cancer Research and Treatment, vol. 188, no. 2, pp. 433-439. https://doi.org/10.1007/s10549-021-06214-7

Measuring Ovarian Escape in Premenopausal Estrogen Receptor-Positive Breast Cancer Patients on Ovarian Suppression Therapy
Burns, E, Koca, E, Xu, J, McLean, E, Lee, R, Patel, T, Chang, J & Niravath, P 2021, , Oncologist, vol. 26, no. 6, pp. e936-e942. https://doi.org/10.1002/onco.13722

A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)
for the fRida Trial Investigators 2021, , Breast Cancer Research and Treatment, vol. 190, no. 2, pp. 265-275. https://doi.org/10.1007/s10549-021-06367-5

A comprehensive overview of metaplastic breast cancer: clinical features and molecular aberrations
Reddy, TP, Rosato, RR, Li, X, Moulder, S, Piwnica-Worms, H & Chang, JC 2020, , Breast Cancer Research, vol. 22, no. 1, 121. https://doi.org/10.1186/s13058-020-01353-z

Antihistamine drug ebastine inhibits cancer growth by targeting polycomb group protein EZH2
Li, Q, Liu, KY, Liu, Q, Wang, G, Jiang, W, Meng, Q, Yi, Y, Yang, Y, Wang, R, Zhu, S, Li, C, Wu, L, Zhao, D, Yan, L, Zhang, L, Kim, JS, Zu, X, Kozielski, AJ, Qian, W, Chang, JC, Patnaik, A, Chen, K & Cao, Q 2020, , Molecular Cancer Therapeutics, vol. 19, no. 10, pp. 2023-2033. https://doi.org/10.1158/1535-7163.MCT-20-0250

Combination PI3K and NOS targeted therapy for metaplastic breast cancer
Reddy, T, Rosato, R, Guzman, L, Qian, W, Zhou, J, Piwnica-Worms, H, Moulder, S & Chang, J 2020, , European Journal of Cancer, vol. 138, pp. S49-S50. https://doi.org/10.1016/S0959-8049(20)31210-7

MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC
Franklin, DA, Sharick, JT, Ericsson-Gonzalez, PI, Sanchez, V, Dean, PT, Opalenik, SR, Cairo, S, Judde, JG, Lewis, MT, Chang, JC, Sanders, ME, Cook, RS, Skala, MC, Bordeaux, J, Orozco Bender, J, Vaupel, C, Geiss, G, Hinerfeld, D & Balko, JM 2020, , JCI insight, vol. 5, no. 15, e134290. https://doi.org/10.1172/jci.insight.134290

Erratum: Bromodomain and extraterminal protein inhibition blocks growth of triple-negative breast cancers through the suppression of aurora kinases (J. Biol. Chem. (2016) 291 (23756-23768) DOI: 10.1074/jbc.M116.738666)
Sahni, JM, Gayle, SS, Weber Bonk, KL, Vite, LC, Yori, JL, Webb, B, Ramos, EK, Seachrist, DD, Landis, MD, Chang, JC, Bradner, JE & Keri, RA 2020, , Journal of Biological Chemistry, vol. 295, no. 27, pp. 9266. https://doi.org/10.1074/jbc.AAC120.014699